Anti-Toxoplasma Performance Panel from SeraCare Provides Broad Sample of New, Challenging Material
Milford, Massachusetts (PRWEB) July 16, 2013 -- SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, announced it has introduced a new AccuSet™ anti-Toxoplasma performance panel. This is the newest addition to the SeraCare line of performance panels designed to help IVD manufacturers effectively challenge new assays during development.
"The demand for Toxoplasma testing in the healthcare industry remains consistently high, requiring the development of new and rigorous testing platforms," said Kim Anderson, Product Manager, IVD Research Business Unit at SeraCare. Screening for the Toxoplasma gondii parasite is performed widely in pregnant women, infants born to infected women, and people with severely weakened or compromised immune systems, creating strong demand for rigorous anti-Toxoplasma assays.
SeraCare’s new AccuSet™ Anti-Toxoplasma gondii Mixed Titer Performance Panel (PTT202) helps IVD manufacturers respond to this market need. It comprises 21 members with a broad range of reactivity for IgG and IgM antibodies and contains donor material representing newer infections, which is critical for IVD manufacturers to effectively challenge new assays.
"Identifying donors who are newly infected with the Toxoplasma gondii parasite but already beginning to demonstrate antibody reactivity is inherently demanding," said Anderson. "SeraCare’s unrivaled sourcing network enabled us to find these donors and develop a panel that can provide our customers with the high degree of confidence they need when challenging the anti-Toxoplasma assays they are currently developing."
SeraCare’s new AccuSet™ Anti-Toxoplasma gondii Mixed Titer Performance Panel is available immediately worldwide. For more information, contact SeraCare Customer Service at 1-800-676-1881 or visit http://www.seracare.com.
About SeraCare Life Sciences, Inc.
SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon™ processed plasma, specialty human blood products and Complete BioCollections™ materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing, and companion diagnostics. For more information, visit http://www.seracare.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at http://www.lindenllc.com.
Marsha Ann Marsh, SeraCare Life Sciences, Inc., http://seracare.com, +1 508.244.6400 6106, [email protected]
Share this article